Senior Investigator Research Interests
Pulmonary arterial hypertension (PAH) is characterized by dysregulated cell proliferation and infiltration of activated inflammatory cells leading to progressive narrowing and obliteration of the distal pulmonary arteries. While current therapeutics reduce pulmonary arterial pressure and increase time to death or transplant, median survival remains only 5-7 years from diagnosis. Unlike selective pulmonary vasodilators alone, approaches directed at inflammatory vascular remodeling have the potential to arrest or even reverse the disease. The focus of the Pulmonary Vascular Biology Lab, led by Dr. Jason Elinoff, is the interplay between lung vascular endothelium and immune effector cells and their contributions to the development and progression of PAH. Current work includes in vitro profiling of human pulmonary artery endothelial cells with heterogeneous PAH-associated molecular defects in order to investigate molecular mechanisms that can exploited therapeutically. The overarching goal of the program is to translate basic science and pre-clinical studies to early phase therapeutic trials in PAH patients.
Meet the Team
Jason Elinoff, M.D.
Dr. Elinoff earned his undergraduate degree in Chemistry from Princeton University and his degree in Medicine from the University of Chicago Pritzker School of Medicine. He went on to complete internship and residency training in Internal Medicine at the Massachusetts General Hospital. Dr. Elinoff completed his fellowship training in Critical Care Medicine at the NIH Clinical Center and Pulmonary and Critical Care Medicine at Johns Hopkins University.